Research map: Real-world effectiveness and safety of belumosudil in pediatric refractory chronic graft-versus-host disease

Back to the article

Papers in this map

  1. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report · Stephanie J. Lee · 2015 · 434 citations · Cited by this paper
  2. Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT · Ryszard Swoboda · 2026 · 1 citation · Related
  3. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study · Corey S. Cutler · 2021 · 353 citations · Cited by this paper
  4. Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols · 2026 · Related
  5. Patient-reported outcomes and health status associated with chronic graft- versus -host disease · Stephanie J. Lee · 2018 · 98 citations · Cited by this paper
  6. Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities · 2026 · Related
  7. Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease · Jeanne M. Palmer · 2013 · 91 citations · Cited by this paper
  8. Institutional risk management for out-of-specification commercial CAR-T products · 2026 · Related
  9. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease · Holly Wobma · 2023 · 25 citations · Cited by this paper
  10. The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P973–P983) · 2026 · Related
  11. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China · Ying Wang · 2024 · 22 citations · Cited by this paper
  12. Vaccination in haematopoietic stem cell transplantation and cellular therapies: consensus, divergence, and uncertainties in global practice · 2026 · Related
  13. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study · Franco Locatelli · 2024 · 18 citations · Cited by this paper
  14. CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy · 2026 · Related
  15. Belumosudil in pediatric patients with chronic graft-versus-host disease after failed multi-line therapy: a case series · Wenting Chen · 2024 · 7 citations · Cited by this paper
  16. The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards · 2026 · Related
  17. Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis · 2026 · Related
  18. EASIX and sC5b-9 for early identification of adults at high risk of developing TA-TMA after allo-HCT · 2026 · Related

Source: OpenAlex (CC0)